Membranous S100A10 Involvement in the Tumor Budding of Colorectal Cancer During Oncogenesis: Report of Two Cases with Immunohistochemical Analysis

Kazumori Arai (m-arai@ny.tokai.or.jp)  
Shizuoka General Hospital

Hisato Ishimatsu  
Shizuoka General Hospital

Tomohiro Iwasaki  
Shizuoka General Hospital

Chinatsu Tsuchiya  
Shizuoka General Hospital

Akihiro Sonoda  
Shizuoka General Hospital

Ko Ohata  
Shizuoka General Hospital

Case report

Keywords: S100A10, Annexin A2, Tumor budding, Poorly differentiated cluster, Colorectal cancer, Immunohistochemistry

DOI: https://doi.org/10.21203/rs.3.rs-70839/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Tumor budding (TB) and poorly differentiated clusters (PDCs) are a sequence of histologic findings that predict worse prognosis and node metastasis in colorectal cancer (CRC). TB and PDC (TB/PDC) are caused by cancer cell detachment and are distinguished by the number of cancer cells that constitute a cell cluster. In short, PDC is regarded as the previous step of TB. TB/PDC and epithelial–mesenchymal transition (EMT) are closely linked, but its pathogenic mechanisms are still unclear. S100A10, a member of the S100 protein family, forms a heterocomplex with annexin A2 (ANX A2) and then translocates to cell membrane from the cytoplasm and plays various roles in cell dynamics, including plasminogen activation. S100A10 is the activation modulator of the heterocomplex and promotes cell invasion. S100A10 is involved in the remodeling of both actin and extracellular matrix (ECM), which is also associated with EMT.

**Case presentation:** In two representative cases of conventional advanced CRC, we immunohistochemically examined S100A10 and ANX A2 expressions in which both TB and PDC were prominent. Both CRCs metastasized to multiple regional lymph nodes. In both cases, a membranous positivity for S100A10 was diffusely found in both tumor buds and PDCs and was observed in the tumor cells protruding toward the stroma, giving rise to TB/PDC. However, even in tumor glands with TB/PDC, the tumor cells with a smooth border around the stroma showed either cytoplasmic fine-granular expression or no positivity. The immunoreactivity for ANX A2 was almost the same as that for S100A10. In the main tumor components without TB/PDC, no distinct positivity was detected at their smooth borders.

**Conclusions:** During oncogenesis, membranous S100A10 has the potential to be related to TB of CRC. This may be due to plasminogen activation, actin remodeling, and interaction with an altered ECM. However, further study is required to confirm this hypothesis.

**Background**

One of the major causes of cancer-related death is colorectal cancer (CRC) [1]. In CRC, tumor budding (TB) and poorly differentiated clusters (PDCs) are new histologic scoring systems that provide more effective prognostic information independently of conventional tumor grading systems, including the tumor, node, and metastasis (TNM) staging system [2, 3]. TB and PDC (TB/PDC) are caused by the detachment of cancer cells from the main tumor body [2–4]. In CRC with prominent TB or PDC, lymph node metastasis and lymphovascular invasion are significantly higher [2, 3, 5, 6] and have the worst prognosis among other cancer types at the same TNM stage [2, 3]. Therefore, TB/PDC may also influence the choice of therapeutic management [3, 5]. TB/PDC are mainly observed at the invasion front of CRC [2–6] and are empirically mixed with each other as a sequence of histologic findings [3, 6]. Both are distinguished by the number of cancer cells (TB: <5 neoplastic cells, PDC: ≥5 neoplastic cells, evaluated on hematoxylin and eosin (H&E)-stained slides) that constitute a cell cluster lacking a glandular structure [2, 3, 5, 6]. In other words, PDC is regarded as the previous step of TB [3, 6]. TB/PDC and epithelial–
mesenchymal transition (EMT) are closely linked [5, 7–9]; however, its pathogenic mechanisms are still unclear. We believe that understanding the protein(s) involved in TB/PDC will help suppress the aggressiveness of CRC.

The S100 protein family, which is composed of 21 members, belongs to the superfamily of calcium-binding proteins [10]. This protein family shows cell-specific expression and has varied functions in cellular processes, such as proliferation, differentiation, and motility/invasion [10]. Furthermore, changes in the expressions and/or functions of the S100 proteins are key steps in cancer development or progression [10]. S100A10, a member of the S100 protein family, is also expressed in various cells, including cancer cells [11, 12]. S100A10 forms a heterocomplex with cytoplasmic annexin A2 (ANX A2), then translocates to the cell membrane from the cytoplasm, and plays various roles in cell dynamics [11, 12]. It is well known that the S100A10-ANX A2 heterocomplex functions as a plasminogen receptor and promotes cell migration/invasion [11–17]. However, several studies have indicated that the S100A10 subunit is the activation modulator of the heterocomplex and directly and specifically plays various roles, including plasminogen activation [12–18]. Furthermore, S100A10 regulates cytoskeletal actin remodeling and facilitates cell spreading [18, 19]. A recent study indicated the involvement of S100A10 in EMT [20]. Regarding its relationship with TB/PDC of CRC, S100A10 and ANX A2 are related not only to poor differentiation but also to the budding of a special type of cancer cells, namely, polyplloid giant cancer cells (PGCCs) [21].

We hypothesized that S100A10 may also be involved in the TB of conventional CRC. We immunohistochemically examined the expressions of S100A10 and ANX A2 in two representative cases of conventional advanced CRC in which both TB and PDC were prominent.

Ethics committee of Shizuoka General Hospital approved the research on S100 protein. (approval number: SGH IRB#2018091/1)

**Case Presentation**

**Case 1**

1. **Case history**

A 70-year-old woman presented with bloody stool for 4.5 months. A sub-circumferential ulcerated tumor and severe stenosis in the sigmoid colon were also revealed by colonoscopy. She had no notable medical history, including cancer, or family history and had no previous history of bloody stool. Enhanced computed tomography (CT) demonstrated the enhancing irregular thickening of the sigmoid colon wall and indicated enlargement of four regional lymph nodes. No metastasis to the other organs was detected. Regarding tumor markers, carcinoembryonic antigen (CEA) level was slightly higher at 5.5 ng/ml (normal range, 0–5 ng/ml), but the cancer antigen 19-9 (CA19-9) level was normal at 13.2 U/ml (normal range, 0–37 U/ml). Colonoscopic biopsy revealed an adenocarcinoma with a tubular growth pattern; hence, laparoscopic sigmoidectomy and lymph node dissection were performed. After the
surgery, the patient received four cycles of XELOX (oxaliplatin combined with capecitabine) for 3 months; the CEA level returned to normal during this period. Mismatch repair (MMR) was genetically evaluated, and the tumor showed proficient MMR. KRAS mutational status was not analyzed. Subsequent chemotherapy was discontinued upon the patient’s request. Fortunately, the patient did not experience recurrence during the follow-up period of 21 months after surgery.

2. Pathology

TB or PDC scoring is performed by counting the number of tumor buds or PDCs under a ×20 objective lens in H&E-stained slides, respectively [3, 4, 6]. Since a ×20 objective lens with a field area of \(1.227 \text{ mm}^2\) was usually used, the counts of tumor buds and PDCs normalized to the recommended field of \(0.785 \text{ mm}^2\) for each scoring [3, 4]. Immunohistochemistry of S100A10, ANX A2, and pan-cytokeratin (pan-CK) was performed with serial tissue sections using Leica Bond-Max (Leica Biosystems, Melbourne, Victoria, Australia). The establishment, characterization, and staining protocol of S100A10 antibody have been previously described [22, 23]. The characterization and staining protocol of ANX A2 antibody have been described elsewhere [22, 24]. In immunostaining for pan-CK, the mouse monoclonal antibody Multi-Cytokeratin (cocktail of two clones, AE1/AE3, Leica Microsystems, Newcastle Upon Tyne, Tyne and Wear, UK) was used at 1:200 dilution, after a 5-min pretreatment with 0.4 mg/mL proteinase K (Dako, Glostrup, Denmark). In TB assessment, it should appear more visible using a pan-CK immunostain; unlike PDC, tumor buds are often difficult to distinguish from the surrounding inflammatory or stromal cells [5, 25].

2.1. Routine pathological findings

Macroscopic examination showed an ulcerated tumor measuring 2.9 × 3.7 cm (Figure 1a). Microscopically, the tumor invaded the subserosa (Figure 1b), but no serosal exposure was noted. The primary tumor component was an adenocarcinoma with a tubular growth pattern (Figure 1c). The aggregates of atypical cells with poor luminal formation were scattered mainly in the invasive front (Figure 1c). In that part, the atypical cells infiltrated the stroma in isolation or in the form of small clusters of less than five cells or more. Immunohistochemically, these cells were diffusely and strongly positive for pan-CK, being regarded as tumor buds or PDCs of the tumor (Figure 1d). The normalized maximal numbers of tumor buds and PDCs were 22 and 12 per field, respectively. Both of these numbers corresponded to score 3 [3, 4], and TB was predominant. In the tumor glands giving rise to TB/PDC, the shape appeared more irregular and protruded into the stroma in a cord-like or small nest appearance. These changes were more clearly observed on a pan-CK immunostain (Figure 1d). In the tumor, the lymphatic invasion was noticeable, and metastases were detected in five regional lymph nodes, corresponding to pathological stage IIIIB (pT3N2aM0) [26].

2.2 Immunohistochemical findings of S100A10 and ANX A2

Membranous positivity for S100A10 was diffusely found in both tumor buds and PDCs (Figure 2). The immunopositivity was observed in the tumor cells protruding toward the stroma (Figure 2). However, even in tumor glands with TB or PDCs, tumor cells with a smooth border around the stroma showed either a
cytoplasmic fine-granular expression or no positivity, except for a reaction at their luminal surface (Figures 2b and 2c). Spindle-shaped stromal cells were negative or faintly positive for S100A10 (Figures 2b, 2c, and 3a). The immunoreactivity for ANX A2 was almost same as that for S100A10 (Figure 3). In the main tumor components without TB/PDC, neither distinct membranous positivity for S100A10 nor for ANX A2 was seen, except for a reaction at their luminal surface (Figure 4).

Case 2

1. Case history

A 65-year-old man presented with bloody stool for 1 month. Patient's colonoscopy revealed a circumferential ulcerated tumor and severe stenosis in the sigmoid colon. He had no notable medical history, including cancer, or family history and had no previous history of bloody stool. Enhanced CT revealed an increasing irregular thickening of the sigmoid colon wall. Enlargement of the lymph nodes and metastasis to the other organs were not noted. CEA and CA19-9 levels were normal (3.9 ng/ml and 16 U/ml, respectively). Laparoscopic sigmoidectomy and lymph node dissection were performed. After the surgery, the patient received chemotherapy for 5.5 months: six cycles of XELOX and two cycles of capecitabine only. However, on magnetic resonance imaging 12 months after surgery, multiple metastases to the liver and para-aortic lymph nodes were detected. The CEA level was higher at 13 ng/ml, but the CA19-9 level remained normal. Genetically, the tumor exhibited proficient MMR. KRAS mutational status also was analyzed but was not detected. One month later, he was transferred to Shizuoka Cancer Center. The patient received chemotherapy for 16 months: 25 cycles of 5-fluorouracil combined with levofolinate and irinotecan (FOLFIRI) with panitumumab and 6 cycles of FOLFIRI alone. The metastases in the liver and lymph nodes are partially reduced, respectively, and the patient survived 30 months after surgery.

2. Pathology

2.1. Routine pathological findings

Macroscopic examination showed an ulcerated tumor measuring 5.2 × 5.5 cm (Figure 5a). Microscopically, the tumor invaded the subserosa (Figure 5b) and was exposed to the serosa. The tumor consisted mainly of an adenocarcinoma with a tubular growth pattern (Figure 5b), and many PDCs with tumor buds were observed around the tumor glands (Figure 5c). PDCs were distributed in the invasion front and inside the tumor (Figure 5b). Many of the PDCs had lacunar spaces, showing a micropapillary carcinoma-like appearance (Figure 5c). The normalized maximal numbers of tumor buds and PDCs were 15 and 21 per field, respectively. Both of these numbers corresponded to score 3 [3, 4], and PDC was predominant. In the tumor glands giving rise to PDCs, the shape appeared more irregular, protruding into the stroma in a cord-like or small nest appearance (Figures 5c and 5d). The tumor metastasized to four regional lymph nodes, corresponding to pathological stage IIIC (T4aN2aM0) [26].
2.2. Immunohistochemical findings of S100A10 and ANX A2

Membranous positivity for S100A10 was diffusely found in PDCs (Figures 6a and 6b). The immunopositivity was observed in the tumor cells protruding into the stroma (Figures 6a and 6b). By contrast, even in tumor glands with PDCs, tumor cells with a smooth border around the stroma showed either cytoplasmic fine-granular expression or no positivity (Figures 6a and 6b). The immunoreactivity for ANX A2 was almost same as that for S100A10 (Figures 6c and 6d). Similarly, the immunopositivities for both proteins were also noted in tumor buds mixed in PDCs (Figure 7). Furthermore, a part of the luminal surface of tumor glands showed a positivity for S100A10 and ANX A2 (Figures 6b and 6d). Spindle-shaped stromal cells were faintly positive or negative for S100A10 and ANX A2 (Figures 6 and 7). In the main tumor components without TB/PDC, neither distinct membranous positivity for S100A10 nor for ANX A2, was noted except for a reaction at their luminal surface (data not shown).

Discussion And Conclusions

In this report, the immunolocalization of S100A10 expression during TB process in two cases of CRC was observed. Both CRCs were advanced-stage cancers with multiple lymph node metastases. The tumor in Case 2 had more predominant PDCs than that in Case 1; however, membranous S100A10 expression was also found in PDCs, that is, the previous step of TB, regardless of their location. In both cases, its expression was also observed in the protruding tumor cells giving rise to TB. This finding suggests that membranous S100A10 is involved in TB of CRC during oncogenesis.

PGCC is an established cancer cell line, which is induced by cobalt chloride or paclitaxel and develops in various organs, including the colon and rectum [21, 27]. A close association among PGCC, TB/PDC, EMT, and tumor differentiation has been suggested [27]. Furthermore, it was reported that S100A10 and ANX A2 are highly expressed in PGCCs with budding [21]. Our case report suggests that S100A10 and ANX A2 are also involved in TB/PDC of conventional CRC in the human body.

Considering TB/PDC, the EMT process of cancer cells can be helpful [7, 8, 28, 29]. In the EMT, the following phenomena occur in cancer cells: activation of several signal transduction pathways, such as RAS, Wnt, and TGF-β; morphological changes followed by the cytoskeleton remodeling; reduction of the contacts with cancer cells or with extracellular matrix (ECM); cancer cell detachment from the main tumor body; degradation of ECM and interaction with altered ECM; and enhancement of cell migration/invasion capacity [28, 29]. Cancer-associated fibroblasts (CAF) were also reported to contribute to these phenomena [29].

In the present tumors, KRAS mutation was not confirmed in any of the tumors. However, previous studies have reported the association between KRAS mutation and a high frequency of TB [8, 30]. S100A10 is also considered to contribute to ECM degradation as well as cancer development, invasion, and metastasis via cell surface plasmin generation and RAS cooperation, including KRAS [11, 12, 17]. A few studies reported the relationship between S100A10 and Wnt pathway [31], whereas a recent study
suggested that S100A10 is a key regulator of the plasminogen activation system during TGF-β-induced EMT [20].

Actin filaments are associated with cell migration and adhesion, as well as the morphological changes of cells [32]. Previous studies suggested that S100A10 acts as a linker between cytoskeletal actin and cell membrane [18, 19] and that the actin dynamics is strongly regulated by S100A10 [18]. Recently, an actin regulator is involved in PDC progression [33]. In malignant tumors, S100A10 interacts with the ECM proteins that form a structural link with the tumor cell surface [34]. S100A10 is involved in cancer cell detachment by cytoskeletal actin remodeling and in the contacts with convenient ECM for cancer cell invasion by ECM remodeling [11, 17–19, 34].

The ANX A2 belongs to a multigene ANX family of calcium-related and membrane-binding proteins and shows cell-specific expression [13–15, 35]. This protein is involved in diverse cellular functions, such as cell motility/invasion, cell polarity, cell adhesion, and cytoskeletal organization, within the cytoplasm and plasma membranes [13–15, 35]. S100A10 is bound to the tyrosine 23-phosphorylated ANX A2 in the cytoplasm, moves to the cell membrane, and stabilizes [11–17, 35]. More than 90% of ANX A2 is localized at the cell membrane as a subunit of the heterocomplex with S100A10, and the remaining is distributed in the cytoplasm and cell membrane as a monomer [13, 35]. Therefore, membranous S100A10 essentially refers to the S100A10 subunit of the heterocomplex [11–13, 17, 18, 34, 35], which is consistent with the immunohistochemical results of the present tumor. Previously, Graauw et al. indicated that tyrosine 23-phosphorylated, membranous ANX A2 induces cell scattering and branching morphogenesis [36]. Tristante et al. reported a strong membranous immunopositivity for ANX A2 in tumor buds of CRC [37]. These reports may have actually pointed out the features that the S100A10 subunit dominates [12–18].

S100A10 positivity at the luminal surface was also found in the adjacent normal crypt (data not shown). S100A10 expression at the luminal surface has also been observed in the mammary ducts, regardless of whether it is cancerous or noncancerous [23], and is considered to be associated with the establishment and maintenance of polarization of glandular epithelial cells, as one of the functions of S100A10-ANX A2 heterocomplex [23, 38, 39, 40]. However, the reason why the protein complex is highly expressed in TB/PDC remains unclear, indicating the collapse of the cell polarity. In poorly differentiated cancer cells, the functions of S100A10-ANX A2 heterocomplex are out of balance and that another function, such as promotion of cell migration/invasion [11, 12, 23, 35, 38, 41], becomes dominant. Hence, future studies will be necessary to confirm the aforementioned research question.

In the present tumors, S100A10 may be poorly related to the stromal cells in TB/PDC because its expression was either absent or very weak. However, recent reports suggested that CAF increase phosphorylated ANX A2 of cancer cells in EMT [42]. The involvement of S100A10 in CAF-induced EMT should be examined in future studies.

This report has several limitations, including patient selection bias, the limited conclusive relationships shown by S100A10 and ANX A2 staining alone, and the intrinsic limitations of a case report.
In conclusion, membranous S100A10 has the potential to be related to TB of CRC during oncogenesis. This may be due to plasminogen activation, actin remodeling, and interaction with an altered ECM [17–19, 34]. It is hypothesized that these functions are more predominant than those of ANX A2 [12–18]. However, further research is required to elucidate differences in the functions of S100A10 and ANX A2.

List Of Abbreviations

ANX A2, annexin A2;
CA19-9, cancer antigen 19-9;
CAF, cancer-associated fibroblasts;
CEA, carcinoembryonic antigen;
CK, cytokeratin;
CRC, colorectal cancer;
CT, computed tomography;
ECM, extracellular matrix;
EMT, epithelial–mesenchymal transition;
H&E, hematoxylin and eosin;
MMR, mismatch repair;
PDC, poorly differentiated cluster;
PGCC, polyploid giant cancer cell;
TB, tumor budding;
TNM, tumor, node, and metastasis

Declarations

Ethics approval and consent to participate

Ethical approval for this report was orally provided by the ethics committee of Shizuoka General Hospital. The conventional way of writing an application and issuing an approval number was not applicable. Written informed consent for participation was obtained from the patients.

Consent for publication
Written informed consent to publish the case details was obtained from the patients.

**Availability of data and materials**

The authors declare that all relevant data are included in this published article and are available within the paper.

**Competing interests**

The authors declare no conflicts of interest regarding the publication of this article.

**Funding**

This report received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Authors’ contributions**

All authors were involved in manuscript preparation. KA designed the study and wrote the initial draft of the manuscript. TI and CT contributed to the analysis and interpretation of immunohistochemical data. HI, AS, and KO contributed to the analysis and interpretation of clinical data and to the obtaining of informed consent. All authors read and approved the final version of the manuscript.

**Acknowledgments**

The authors would like to thank Enago (www.enago.jp) for providing the English language review.

**Author’s information**

KA: Senior head pathologist; HI: Senior head surgeon; TI: Head pathological technologist; CT: Subhead pathological technologist; AS: Head of Clinical Research (Former chief clinical laboratory technician); and KO: Director of Gastroenterological Surgery.

**References**

[1] Global Burden of Disease Cancer Collaboration. Global regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017. A systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5:1749-68.
[2] van Wrk CH, Roseweir A, Alexander P, Park JH, Horgan PG, McMillan DC, et al. The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer. Ann Surg Oncol. 2019;26:4397-404.

[3] Ueno H, Kajiwara Y, Shimazaki H, Shinto E, Hashiguchi Y, Nakanishi K, et al. New criteria for histologic grading of colorectal cancer. Am J Surg Pathol. 2012;36:193-201.

[4] Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the international tumor budding consensus conference (ITBCC) 2016. Modern Pathol. 2017;30:1299-311.

[5] Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer-ready for diagnostic practice? Hum Pathol. 2016;47:4-11.

[6] Yang M, Rehmen AU, Zuo C, Sheehan CE, Lee EC, Lin J, et al. A novel histologic grading scheme based on poorly differentiated clusters is applicable to treated rectal cancer and is associated with established histopathological prognosticators. Cancer Med. 2016;5:1510-8.

[7] Lugli A, Karamitopoulou E, Zlobec I. Tumor budding: a promising parameter in colorectal cancer. Brit J Cancer. 2012;106:1713-7.

[8] Dawson H, Lugli A. Molecular and pathogenetic aspects of tumor budding in colorectal cancer. Front Med. 2015;2:1-11.

[9] Ueno H, Shinto E, Kajiwara Y, Fukazawa S, Shimazaki H, Yamamoto J, et al. Prognostic impact of histological categorization of epithelial-mesenchymal transition in colorectal cancer. Br J Cancer. 2014;111:2082-90.

[10] Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer. 2015;15:96-109.

[11] Tantyo NA, Karyadi AS, Rasman SZ, Salim MRG, Devina A, Sumarpo A. The prognostic value of S100A10 expression in cancer (Review). Oncol Lett. 2018;1-8.

[12] Li C, Ma Y, Fei F, Zheng M, Li Z, Zhao Q, et al. Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases. J Cancer. 2020;11:826-36.

[13] Kassam G, Le BH, Choi KS, Kang HM, Fitzpatrick SL, Louie P, et al. The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. Biochemistry. 1998;37:16958-66.

[14] MacLeod TJ, Kwon M, Filipenko NR, Waisman DM. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits. Characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem. 2003;278:25577-84.
[15] Kwon M, MacLeod TJ, Zhang Y, Waisman DM. S100A10, annexin A2, and annexin A2 heterotetramer as candidate plasminogen receptors. *Front Biosci.* 2005;10:300-25.

[16] Madureira PA, Surette AP, Phipps KD, Taboski MAS, Miller VA, Waisman DM. The role of the annexin A2 heterotetramer in vascular fibrinolysis. *Blood.* 2011;118:4789-97.

[17] Madureira PA, Bharadwaj AG, Bydoun M, Garant K, O’Connell P, Lee P, et al. Cell surface protease activation during RAS transformation: critical role of the plasminogen receptor, S100A10. *Oncotarget.* 2016;7:47720-37.

[18] Jung MJ, Murzik U, Wehder L, Hemmerich P, Melle C. Regulation of cellular actin architecture by S100A10. *Exp Cell Res.* 2010;316:1234-40.

[19] Sayeed S, Asano E, Ito S, Ohno K, Hamaguchi M, Senga T. S100A10 is required for the organization of actin stress fibers and promotion of cell spreading. *Mol Cell Biochem.* 2013;374:105-11.

[20] Bydoun M, Sterea A, Weaver ICG, Bharadwaj AD, Waisman DM. A novel mechanism of plasminogen activation in epithelial and mesenchymal cells. *Sci Rep.* 2018;8:1-17.

[21] Fei F, Liu K, Li C, Du J, Wei Z, Li B, et al. Molecular mechanisms by which S100A4 regulates the migration and invasion of PGCCs with their daughter cells in human colorectal cancer. *Front Oncol.* 2020;10:1-13.

[22] Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T, et al. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. *Cancer Sci.* 2006;98:77-82.

[23] Arai K, Iwasaki T, Sonoda A, Endo A. Membranous overexpression of S100A10 is associated with a high-grade cellular status of breast carcinoma. *Med Mol Morphol.* 2020;53:104-14.

[24] Arai K, Hirose M. Annexin A2 expression in aerogenous metastasis of pulmonary invasive mucinous adenocarcinoma; a case report including immunohistochemical analysis. *Case Rep Oncol Med.* 2019;2019:5064852.

[25] Kai K, Aishima S, Aoki S, Takase Y, Uchihashi K, Masuda M, et al. Cytokeratin immunohistochemistry improves interobserver variability between unskilled pathologists in the evaluation of tumor budding in T1 colorectal cancer. *Pathol Int.* 2016;66:75-82.

[26] Brierley JD, Gospodarowicz MK, Wittekind C, eds. Union for International Cancer Control (UICC): *TNM Classification of Malignant Tumours (8th Edition).* USA: Wiley-Blackwell; 2017.

[27] Zhang S, Zhang D, Yang Z, Zhang X. Tumor budding, micropapillary pattern, and polyploidy giant cancer cells in colorectal cancer: current status and future prospects. *Stem Cells Int.* 2016:1-8.
[28] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178-96.

[29] Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69-84.

[30] Barresi V, Bonetti LR, Bettelli S. KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases. Pathology. 2015;47:551-6.

[31] Shan X, Miao Y, Fan R, Qian H, Chen P, Liu H, et al. MiR-590-5P inhibits growth of HepG2 cells via decrease of S100A10 expression and inhabitation of the Wnt pathway. Int J Mol Sci. 2013;14:8556-69.

[32] Gardel ML, Schneider IC, Aratyn-Schaus Y, Waterman CM. Mechanical integration of actin and adhesion dynamics in cell migration. Annu Rev Cell Dev Biol. 2010;26:315-33.

[33] Akikawa A, Fujita H, Kosaka T, Minato H, Kiyokawa E. Clinicopathological significance of heterogeneic Ezrin expression in poorly differentiated clusters of colorectal cancers. Cancer Sci. 2019;110:2667-75.

[34] Mai J, Waisman DM, Sloane BF. Cell surface complex of cathepsin B/ annexin II tetramer in malignant progression. Biochim Biophys Acta. 2000;1477:215-30.

[35] Grindheim AK, Saraste J, Vedeler A. Protein phosphorylation and its role in the regulation of Annexin A2 function. Biochim Biophys Acta -General Subjects. 2017;1861:2515-29.

[36] de Graauw M, Tijdens I, Smeets MB, Hensbergen PJ, Deelder AM, van de B. Water: Annexin A2 phosphorylation mediates cell scattering and branching morphogenesis via coflin activation. Mol Cell Biol. 2008;28:1029-40.

[37] Tristante E, Martinez CM, Jimenez S, Mora L, Carballo F, Martinez-Lacaci I, et al. Association of a characteristic membrane pattern of annexin A2 with high invasiveness and nodal status colon adenocarcinoma. Transl Res. 2015;166:196-206.

[38] Rescher U, Gerke V. S100A10/ p11: family, friends and functions. Eur J Physiol. 2008;455:575-82.

[39] Roman-Fernandez A, Bryant DM. Complex polarity: building multicellular tissues through apical membrane traffic. Traffic. 2016;17:1244-61.

[40] Arai K, Iwasaki T, Tsuchiya C, Sonoda A. Involvement of Annexin A2 expression and apoptosis in reverse polarization of invasive micropapillary carcinoma of the breast. Case Rep Pathol. 2020;2020:9242305.
[41] Arai K, Iwasaki T, Tuchiya C, Sonoda A. Annexin A2 expression in the aerogenous spread of pulmonary invasive mucinous adenocarcinoma with gastric lineage. Case Rep Oncol Med. 2020;2020:2492636.

[42] Yi Y, Zeng S, Wang Z, Wu M, Ma Y, Ye X, et al. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling. Biochim Biophys Acta. 2018;1864:793-803.